Engineered immune cells take on stomach cancer in Late-Stage trial

NCT ID NCT07103668

Recruiting now Disease control Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new treatment called IMC002, which uses a patient's own immune cells (CAR T-cells) engineered to target a protein called CLDN18.2 found on some stomach cancer cells. The study includes 150 adults with advanced stomach cancer that has not responded to at least two prior treatments. Participants will receive either IMC002 or standard chemotherapy to see which better controls the cancer and extends survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR T-cells (IMC002)
What this could lead to: If successful, this could offer a new treatment option for people with advanced gastric cancer that has not responded to other therapies.
What could go wrong: This is still an experimental therapy. CAR T-cells can cause serious side effects, and it is not yet known if they work better than chemotherapy in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Chinese PLA General Hospital, Beijing
RECRUITING

Beijing, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.